Search for other papers by Shi Hui Junice Wong in
Google Scholar
PubMed
treatment of Graves’ disease is well described and has been shown to have good results with an acceptable side effect profile. Radiation-induced thyroiditis can occur in 1–5% of hyperthyroid patients and usually resolves on its own. It usually manifests
Search for other papers by Sun Mi Park in
Google Scholar
PubMed
Search for other papers by Yoon Young Cho in
Google Scholar
PubMed
Search for other papers by Ji Young Joung in
Google Scholar
PubMed
Search for other papers by Seo Young Sohn in
Google Scholar
PubMed
Search for other papers by Sun Wook Kim in
Google Scholar
PubMed
Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed
according to the Werner's criteria [ 14 , 15 ] as absent (class 0-1) or present (class 2-6). Remission was defined as a euthyroid state maintained for at least more than a year: relapse was defined as apparent recurrence of hyperthyroidism with laboratory
Search for other papers by Eyun Song in
Google Scholar
PubMed
Search for other papers by Jonghwa Ahn in
Google Scholar
PubMed
Search for other papers by Hye-Seon Oh in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Search for other papers by Won Bae Kim in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Tae Yong Kim in
Google Scholar
PubMed
Introduction The incidence of body weight change (BWC) in patients with overt thyroid dysfunction exceeds 50%, representing one of the most common symptoms [ 1 , 2 ]. Overt hyperthyroidism (OHyper) is frequently associated with weight loss
Search for other papers by Christian Trummer in
Google Scholar
PubMed
Search for other papers by Hannes Reiher in
Google Scholar
PubMed
Search for other papers by Verena Theiler-Schwetz in
Google Scholar
PubMed
Search for other papers by Marlene Pandis in
Google Scholar
PubMed
Search for other papers by Christian Gstettner in
Google Scholar
PubMed
Search for other papers by Peter Potzinger in
Google Scholar
PubMed
Search for other papers by Tilman Keck in
Google Scholar
PubMed
Search for other papers by Thomas R. Pieber in
Google Scholar
PubMed
Institute of Pathology, Medical University of Graz, Graz, Austria
Institute for Clinical Pathology, Johannes Kepler University, Linz, Austria
Search for other papers by Sigurd Lax in
Google Scholar
PubMed
Department of Neuropathology, Institute of Pathology, Medical University of Graz, Graz, Austria
Department of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria
Search for other papers by Johannes Haybaeck in
Google Scholar
PubMed
Search for other papers by Vinzenz Stepan in
Google Scholar
PubMed
Search for other papers by Stefan Pilz in
Google Scholar
PubMed
What Is Known about This Topic? The differential diagnosis of secondary hyperthyroidism may lead to several challenges. Although very rare, ectopic thyrotropin-secreting neuroendocrine pituitary tumors (TSH-PitNETs) need to be
Search for other papers by Hirosuke Danno in
Google Scholar
PubMed
Search for other papers by Eijun Nishihara in
Google Scholar
PubMed
Search for other papers by Kazuyoshi Kousaka in
Google Scholar
PubMed
Search for other papers by Tomohiko Nakamura in
Google Scholar
PubMed
Search for other papers by Toshihiko Kasahara in
Google Scholar
PubMed
Search for other papers by Takumi Kudo in
Google Scholar
PubMed
Search for other papers by Mitsuru Ito in
Google Scholar
PubMed
Search for other papers by Shuji Fukata in
Google Scholar
PubMed
Search for other papers by Mitsushige Nishikawa in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
]. Methimazole was switched to propylthiouracil or potassium iodide when adverse reactions occurred. The initial dose of radioiodine-131 was based on 13 mCi and determined by each physician with reference to thyroid size and function. If hyperthyroidism continued
Search for other papers by Elena Sabini in
Google Scholar
PubMed
Search for other papers by Ilaria Ionni in
Google Scholar
PubMed
Search for other papers by Roberto Rocchi in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Michele Marinò in
Google Scholar
PubMed
deterioration of Graves’ orbitopathy in patients with Graves’ hyperthyroidism. A similar release of autoantigens may occur at the eye level resulting in the development of Graves’ orbitopathy. What Does This Case Report Add? To our knowledge
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine and School of Medicine, Seoul, Republic of Korea
Search for other papers by Meihua Jin in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea
Search for other papers by Ahreum Jang in
Google Scholar
PubMed
Search for other papers by Chae A Kim in
Google Scholar
PubMed
Search for other papers by Tae Yong Kim in
Google Scholar
PubMed
Search for other papers by Won Bae Kim in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Introduction Graves’ hyperthyroidism is an autoimmune disease in which thyrotropin (thyroid-stimulating hormone (TSH)) receptor antibody (TRAb) stimulates thyroid follicular cells, resulting in thyrotoxicosis and enlargement of the thyroid
Search for other papers by R. Paschke in
Google Scholar
PubMed
Search for other papers by M. Niedziela in
Google Scholar
PubMed
Search for other papers by B. Vaidya in
Google Scholar
PubMed
Search for other papers by L. Persani in
Google Scholar
PubMed
Search for other papers by B. Rapoport in
Google Scholar
PubMed
Search for other papers by J. Leclere in
Google Scholar
PubMed
Introduction Familial non-autoimmune autosomal dominant hyperthyroidism (FNAH) and persistent sporadic congenital non-autoimmune hyperthyroidism (PSNAH) are rare forms of hyperthyroidism caused by germline mutations in the thyroid
Search for other papers by Bernadette Biondi in
Google Scholar
PubMed
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by David S. Cooper in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Peter Laurberg in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Definition, Aetiology and Prevalence of Endogenous Subclinical Hyperthyroidism The definition of subclinical hyperthyroidism (SHyper) is based exclusively on laboratory findings, not clinical criteria [ 1 , 2 , 3 , 4 , 5 , 6 ]. SHyper is
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by Lazlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Kris Poppe in
Google Scholar
PubMed
Search for other papers by Simon H. Pearce in
Google Scholar
PubMed
Epidemiology and Pathogenesis Hyperthyroidism occurs due to an inappropriately high synthesis and secretion of thyroid hormone (TH) by the thyroid [ 1 ]. TH increases tissue thermogenesis and the basal metabolic rate, and reduces serum